Trafficking of tumor peptide-specific cytotoxic T lymphocytes into the tumor microcirculation

International Journal of Cancer

Volumn 110, Issue 2, 2004, Pages 239-244

  Ali, Selman ^a   Ahmad, Murrium ^a   Lynam, June ^a   Rees, Robert C ^a   Brown, Nicola ^b  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Adoptive transfer; Cytotoxic T lymphocytes; Trafficking

Indexed keywords

AH 1 PEPTIDE; BETA GALACTOSYLPEPTIDE; CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CELL ACTIVITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CREMASTER MUSCLE; CYTOTOXIC T LYMPHOCYTE; HERPES SIMPLEX VIRUS; IMMUNE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MICROCIRCULATION; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TUMOR CELL LINE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL MOVEMENT; FLOW CYTOMETRY; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED BALB C; MICROCIRCULATION; NEOPLASMS, EXPERIMENTAL; SIMPLEXVIRUS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 2342475731     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20113     Document Type: Article

References (25)

1. Ali SA, Lynam J, McLean CS, Entwisle C, Loudon P, Rojas JM, McArdle SE, Li G, Mian S, Rees RC. Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocytemacrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity. J Immunol 2002;168:3512-9.
2. Wang R, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol Rev 1999;170:85-100.
3. Sutmuller RP, Schurmans LR, van Duivenvoorde LM, Tine JA, van Der Voort EI, Toes RE, Melief CJ, Jager MJ, Offringa R. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100. J Immunol 2000;165:7308-15.
4. Merchant RE, Baldwin NG, Rice CD, Bear HD. Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes. Neurol Res 1997;19:145-52.
5. Parmiani G. An explanation of the variable clinical response to interleukin 2 and LAK cells. Immunol Today 1990;11:113-5.
6. Labarriere N, Pandolfino MC, Gervois N, Khammari A, Tessier MH, Dreno B, Jotereau F. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother 2002;51:532-8.
7. Wood GW, Holladay FP, Turner T, Wang YY, Chiga M. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. J Neurooncol 2000;48:113-20.
8. Johnson SK, Kerr KM, Chapman AD, Kennedy MM, King G, Cockbum JS, Jeffrey RR. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 2000;27:27-35.
9. Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, Marincola FM, Wang E, Young HA, Murphy PM, Hwu P. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther 2002;13:1971-80.
10. Soler D, Humphreys TL, Spinola SM, Campbell JJ. CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood 2003; 101:1677-82.
11. + T cells represent major subsets of human peripheral blood memory T cells migrating in response to CCL1/I-309. Eur J Immunol 2002;32:3506-14.
12. + T cells. Immunol Rev 2002;186:221-33.
13. Kim CH, Johnston B, Butcher EC. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood 2002;100:11-6.
14. Ali SA, Rees RC, Anderson DQ, Reed MW, Goepel JR, Brown NJ. Trafficking of "immune" CD4(+)/CD8(+)T-lymphocytes into the RENCA tumor microcirculation in vivo in mice. Br J Cancer 2000; 83:1061-8.
15. Brown NJ, Ali S, Reed MW, Wiltrout R, Rees RC. Trafficking of activated lymphocytes into the RENCA tumor microcirculation in vivo in mice. Br J Cancer 1997;76:1572-8.
16. Brown NJ, Reed MW. Leucocyte interactions with the mouse cremaster muscle microcirculation in vivo in response to tumor-conditioned medium. Br J Cancer 1997;75:993-9.
17. Peng L, Krauss JC, Plautz GE, Mukai S, Shu S, Cohen PA. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics. J Immunol 2000;165:7116-24.
18. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002;99:16168-73.
19. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
20. Plautz GE, Touhalisky JE, Shu S. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cell Immunol 1997;178:101-7.
21. Ryan MH, Bristol JA, McDuffie E, Abrams SI. Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope. J Immunol 2001;167:4286-92.
22. Todryk S, McLean C, Ali S, Entwistle C, Boursnell M, Rees R, Vile R. Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer. Hum Gene Ther 1999;10:2757-68.
23. Dillman RO, Hurwitz SR, Schiltz PM, Barth NM, Beutel LD, Nayak SK, O'Connor AA. Tumor localization by tumor infiltrating lymphocytes labeled with indium-111 in patients with metastatic renal cell carcinoma, melanoma, and colorectal cancer. Cancer Biother Radiopharm 1997;12:65-71.
24. Hazelrigg MR, Hirsch JI, Merchant RE. Distribution of adoptively transferred, tumor-sensitized lymphocytes in the glioma bearing rat. J Neurooncol 2002;60:143-50.
25. Meidenbauer N, Marienhagen J, Laumer M, Vogl S, Heymann J, Andreesen R, Mackensen A. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol 2003;170:2161-9.